News blog

Panel rejects experimental chronic fatigue syndrome drug

A chronic fatigue syndrome drug that spent decades in clinical development and won fervent patient support, has been turned down for approval by a committee of advisers to the US Food and Drug Administration (FDA) who voted 9-4 against it. The drug, named Ampligen (rintatolimod), has not been shown to be effective or safe, the committee determined on 20 December. 

BACK TO ARTICLE

Tell a Friend

Please ensure that your friend is content to receive an email from us with a link to the article. Select the following link to view our Privacy Policy.

BACK TO ARTICLE